Stock Financial Ratios, Dividends, Split History

MDC / M.D.C. Holdings, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,694.36
Enterprise Value ($M)2,175.53
Book Value / Share25.07
Price / Book1.23
NCAV ($M)-1,373.01
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Shares Outstanding Basic 55,663,908
Common Stock Shares Outstanding 56,123,228
Weighted Average Number Of Diluted Shares Outstanding 56,901,461
Common Shares Outstanding 56,123,228
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.06
Return on Equity (ROE)0.11
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Real Estate Revenue Net0.00
Financial Services Revenue0.00
Home Building Revenue0.00
Net Income141.84
Earnings Per Share Diluted2.48
Earnings Per Share Basic2.54
Cash Flow Statement (mra) ($M)
Cash From Operations65.47
Cash from Investing57.79
Cash from Financing57.79
Identifiers and Descriptors
Central Index Key (CIK)773141
Related CUSIPS
552676958 055267610 552676908

Split History

Stock splits are used by M.D.C. Holdings, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

D.R. Horton's (DHI) Backlog Solid, Material Costs Rise

2018-05-18 zacks
With robust backlog, a well-stocked inventory of land, lots and homes in place and accretive acquisitions, D.R. Horton (DHI - Free Report) is expected to continue its stellar performance through fiscal 2018. At the end of the second quarter of fiscal 2018, sales order backlog increased 8.4% to 15,841 homes. Backlog value increased 9% to $4.8 billion. The company’s first-half performance was impressive with Homebuilding revenues increasing 15% and earnings rising 22. (3-0)

Is M.D.C. Holdings (MDC) a Great Stock for Value Investors?

2018-05-18 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? (1-0)

Is the Slump in Starts & Permits a Real Threat to Housing?

2018-05-17 zacks
New residential construction in the United States decreased more than expected in April 2018 as lesser starts of apartment buildings overshadowed a modest improvement in single-family structures. Notably, this is the second time in the last four months that housing starts has toppled. Per the latest jointly released report from the U.S. Census Bureau and the U.S. Department of Housing and Urban Development, construction of new homes fell 3. (12-0)

4 Factors that Emphasize William Lyon Homes' Solid Prospects

2018-05-15 zacks
William Lyon Homes’s (WLH - Free Report) shares have gained 2% in the past three months against its industry’s decline of 6.7%. Also, the company has outperformed the industry in the 12-week and 52-week time frame, lending the stock a Momentum Score of B. The company’s consistent bottom-line outperformance, on the back of a healthy housing industry and strong demand trends, has imparted considerable momentum to the stock. (9-0)

5 Homebuilding Stocks With Solid Momentum Post Q1 Earnings

2018-05-14 investorplace
U.S. homebuilding companies have been riding high in recent years and the March quarter was no exception. Most of the notable homebuilders reported stellar results, beating on both top and bottom lines. The positive momentum is likely to continue through 2018 given the solid earnings outlook and favorable economic fundamentals. (46-0)

CUSIP: 552676108